2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

J Am Coll Cardiol. 2019 Jun 25;73(24):e285-e350. doi: 10.1016/j.jacc.2018.11.003. Epub 2018 Nov 10.
No abstract available

Keywords: ACC/AHA Clinical Practice Guidelines; Guidelines; LDL-cholesterol; biomarkers; cardiovascular disease; cholesterol; coronary artery calcium score; diabetes mellitus; drug therapy; ezetimibe; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; pharmacological; primary prevention; proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors; risk assessment; risk reduction discussion; risk treatment discussion; secondary prevention.

Publication types

  • Practice Guideline

MeSH terms

  • American Heart Association
  • Anticholesteremic Agents / pharmacology
  • Biomarkers / blood
  • Cardiology* / methods
  • Cardiology* / standards
  • Cardiovascular Diseases / prevention & control*
  • Cardiovascular Diseases / psychology
  • Ezetimibe / pharmacology*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Hypercholesterolemia* / blood
  • Hypercholesterolemia* / diagnosis
  • Hypercholesterolemia* / epidemiology
  • Hypercholesterolemia* / therapy
  • Medication Therapy Management / standards
  • Proprotein Convertase 9 / antagonists & inhibitors*
  • Risk Assessment / methods
  • Risk Reduction Behavior
  • United States

Substances

  • Anticholesteremic Agents
  • Biomarkers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Ezetimibe